Tomáš Cihlář

机构：College of San Mateo, Gilead Sciences (United States) · ORCID：0000-0001-6840-0885

发表论文 235 篇 · 总被引 23053 次 · h-index 65

代表论文

• Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys (2023 · Journal of Medicinal Chemistry · 被引 63)
• Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent (2023 · Molecular Pharmaceutics · 被引 53)
• Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus (2024 · Science · 被引 42)
• Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates (2025 · Nature Medicine · 被引 28)
• The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses (2024 · Science Translational Medicine · 被引 22)
• The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection (2025 · Science Advances · 被引 19)